Reply to M.J. Hall et al and K.N. Maxwell et al

Affiliations

Comment

Jennifer E Axilbund. J Clin Oncol. 2016 Dec.

. 2016 Dec;34(34):4187.

doi: 10.1200/JCO.2016.69.1964. Epub 2016 Oct 31.

¹ Jennifer E. Axilbund, The Johns Hopkins University School of Medicine, Baltimore, MD.

No abstract available

Comment on

Panel Testing Is Not a Panacea.
Axilbund JE. Axilbund JE. J Clin Oncol. 2016 May 1;34(13):1433-5. doi: 10.1200/JCO.2015.65.5522. Epub 2016 Mar 14. J Clin Oncol. 2016. PMID: 26976416 No abstract available.
Population Frequency of Germline BRCA1/2 Mutations.
Maxwell KN, Domchek SM, Nathanson KL, Robson ME. Maxwell KN, et al. J Clin Oncol. 2016 Dec;34(34):4183-4185. doi: 10.1200/JCO.2016.67.0554. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27551127 No abstract available.
Multigene Panels to Evaluate Hereditary Cancer Risk: Reckless or Relevant?
Hall MJ, Obeid E, Daly MB. Hall MJ, et al. J Clin Oncol. 2016 Dec;34(34):4186-4187. doi: 10.1200/JCO.2016.68.6725. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27551136 No abstract available.